March 1, 2016
(Washington Post) – Within days, a few doses of ZMapp were on their way in frozen vials to West Africa, where they were administered to both workers. Both recovered from the usually fatal hemorrhagic disease. It was impossible then, and remains impossible now, to determine what part the medicine might have played in Brantly and Writebol’s survival. But the first controlled clinical trial of the medication shows promising results, according to federal authorities and the company that makes the drug, which said it will push forward with requests for a license from the Food and Drug Administration.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.